Unified In-House Platform for Assay Development and Data Integrity for GMP‑Ready NGS Analytics
April 16, 2026
Cell and gene therapies (CGTs) present unique challenges, including short shelf life, manufacturing complexity, excessive costs, and stringent evaluation of all components throughout development and manufacturing. CGT development requires robust Chemistry, Manufacturing, and Controls (CMC), along with advanced analytics and assay development capabilities to ensure product quality, safety, and regulatory compliance.
Next‑generation sequencing (NGS) has become a central analytical technology to address these challenges by enabling sensitive and comprehensive genetic characterization and enhanced biosafety. Regulatory agencies increasingly recognize NGS as a replacement for traditional in vivo testing. However, outsourcing NGS assays often becomes a bottleneck, with long turnaround times, rising per‑sample costs, and limited flexibility. Custom‑developed internal pipelines bring a separate set of challenges, as they often constrain bioinformatics talent with routine tasks and are costly and complex to validate.
Genedata Selector® addresses these challenges by providing an established, validation‑ready, and fully scalable in‑house NGS analysis platform with enterprise‑grade reliability, scientific flexibility, and regulatory compliance across analytics and assay development.
